ArticleAlzheimer's research & therapy2017
Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Article in Alzheimer's research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 4 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Pooled it
- Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Pooled it
- Diagnostic performance of molecular imaging methods in predicting the progression from mild cognitive impairment to dementia: an updated systematic review.European journal of nuclear medicine and molecular imaging · 2024Pooled it
- Amyloid-β PET in Alzheimer's disease: A systematic review and Bayesian meta-analysis.Brain and behavior · 2023Pooled it
- Sequential scans ofJapanese journal of radiology · 2026Article
- Lecanemab approval in EU: what should we be ready for?- the EANM perspective.European journal of nuclear medicine and molecular imaging · 2025Article
- Applying machine learning to high-dimensional proteomics datasets for the identification of Alzheimer's disease biomarkers.Fluids and barriers of the CNS · 2025Article
- Insights from a 7-Year Dementia Cohort (VALCODIS): ApoE Genotype Evaluation.Journal of clinical medicine · 2024Article
- A Comparative Analysis of Two Automated Quantification Methods for Regional Cerebral Amyloid Retention: PET-Only and PET-and-MRI-Based Methods.International journal of molecular sciences · 2024Article
- Deep learning-based amyloid PET harmonization to predict cognitive decline in non-demented elderly.Radiology advances · 2024Article
- Amyloid-PET imaging predicts functional decline in clinically normal individuals.Alzheimer's research & therapy · 2024Article
- Contribution of Global Amyloid-PET Imaging for Predicting Future Cognition in the MEMENTO Cohort.Neurology · 2024Article
- A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles.Brain communications · 2024Review
- Prediction of Conversion from Mild Cognitive Impairment to Alzheimer's Disease Using Amyloid PET and Brain MR Imaging Data: A 48-Month Follow-Up Analysis of the Alzheimer's Disease Neuroimaging Initiative Cohort.Diagnostics (Basel, Switzerland) · 2023Article
- PET molecular imaging for pathophysiological visualization in Alzheimer's disease.European journal of nuclear medicine and molecular imaging · 2023Review
- Constructing a prognostic risk model for Alzheimer's disease based on ferroptosis.Frontiers in aging neuroscience · 2023Article
- Biomarkers for the Diagnosis of Alzheimer's Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria.International journal of molecular sciences · 2022Review
- Quantification of amyloid PET for future clinical use: a state-of-the-art review.European journal of nuclear medicine and molecular imaging · 2022Review
- Grey matter network markers identify individuals with prodromal Alzheimer's disease who will show rapid clinical decline.Brain communications · 2022Article
- Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer's disease.Alzheimer's research & therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe relative performance of semi-quantitative amyloid positron emission tomography (PET) and cerebrospinal fluid (CSF) markers in diagnosing Alzheimer's disease (AD) and predicting the cognitive evolution of patients with mild cognitive impairment (MCI) is still debated.
methodsSubjects from the Alzheimer's Disease Neuroimaging Initiative 2 with complete baseline cognitive assessment (Mini Mental State Examination, Clinical Dementia Rating [CDR] and Alzheimer's Disease Assessment Scale-Cognitive Subscale [ADAS-cog] scores), CSF collection (amyloid-β
resultsThe cross-sectional study included 677 participants and revealed that pontine and composite SUVr values were better classifiers (AUC 0.88, diagnostic accuracy 85%) than CSF markers (AUC 0.83 and 0.85, accuracy 80% and 75%, for Aβ and tau, respectively). SUVr was a strong independent determinant of cognition in multivariate regression, whereas Aβ was not; tau was also a determinant, but to a lesser degree. Among the 396 patients from the longitudinal study, 82 (21%) converted to AD within 22 ± 13 months. Optimal SUVr thresholds to differentiate AD converters were quite similar to those of the cross-sectional study. Composite SUVr was the best AD classifier (AUC 0.86, sensitivity 88%, specificity 81%). In multivariate regression, baseline cognition (CDR and ADAS-cog) was the main predictor of subsequent cognitive decline. Pontine and composite SUVr were moderate but independent predictors of final status and CDR/ADAS-cog progression rate, whereas baseline CSF markers had a marginal influence. The adjusted HRs for AD conversion were 3.8 (p = 0.01) for PET profile, 1.2 (p = ns) for Aβ profile and 1.8 (p = 0.03) for tau profile.
conclusionsSemi-quantitative amyloid PET appears more powerful than CSF markers for AD grading and MCI prognosis in terms of cognitive decline and AD conversion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.